FDA Accepts Nanoscopes's Optogenetic Gene Therapy BLA

Eyetube

The FDA accepts a biologics license application (BLA) for a first-of-its-kind optogenetic gene therapy for RP; a software upgrade from Heru combines several pretesting assessments into a single guided workflow; and a new FDA-approved overnight orthokeratology lens is launched in the US. Learn more about your ad choices. Visit megaphone.fm/adchoices

FDA Accepts Nanoscopes's Optogenetic Gene Therapy BLA

Eyetube

Novel Approaches to Minimally Invasive Bleb Surgery

Two technologies offer safer alternatives to traditional filtering procedures.

Shan C. Lin, MD, and Nir Shoham-Hazon, MD

Glaucoma Today

Key Takeaways Minimally invasive bleb surgery, or MIBS, has emerged as a distinct category within the MIGS spectrum to address a treatment gap for patients with glaucoma who have visual field loss and need enhanced IOP control but do not necessarily require extremely low IOPs. Two new technologies offer safer alternatives to traditional filtering procedures. An Implant-Free Path to Minimally Invasive Subconjunctival Filtration By Shan C. Lin, MD MIGS has allowed glaucoma surgeons to treat early glaucoma, including ocular hypertension and mild to moderate disease, often in conjunction with cataract surgery. For more advanced disease, such as moderate to severe glaucoma, or in eyes with very high IOP, filtration surgeries are the most effective procedures to lower pressure and prevent progressive vision loss. However, trabeculectomy and tube shunt surgery have relatively high rates of complications, including hypotony, bleb leak, infection, and tube erosion. Minimally invasive bleb surgery (MIBS) has emerged as a distinct category within the MIGS spectrum to address a treatment gap for patients with glaucoma who have visual field loss and need enhanced IOP control but do not necessarily require extremely low IOPs. A SAFER WAY TO ACHIEVE FILTRATION MIBS encompasses procedures that achieve substantial IOP lowering through the creation of a subconjunctival filtering bleb via a microinvasive ab interno or ab externo approach. These procedures result in limited tissue disruption and demonstrate a safety profile that is comparable to that of angle-based MIGS. The Aqualumen (PLU Ophthalmic) is a novel, implant-free surgical device that creates a controlled transscleral outflow pathway to reduce IOP in patients with glaucoma.

Featured Podcasts

Ophthalmology off the Grid

Open. Outspoken. It's Ophthalmology off the Grid—an honest look at controversial topics in the field.

View Feed

New Retina Radio

New Retina Radio is a place to hear stories about retina that are told nowhere else.

View Feed

Eyewire News: The Podcast

Get the latest information and breaking news in the ophthalmic field.

View Feed

EyewireTV

09.30.2026

09.30.2026

Kodiak Reports Phase 3 Trial Meets Primary Endpoints for Zenkuda in Wet AMD

European Commission Approves Roche’s Susvimo for Wet AMD

Merck's Remigromig Meets Primary Endpoint in Phase 2b/3 BRUNELLO Trial for DME

Eyewire News

SpyGlass Pharma Acquires Advanced Vision Science for Approximately $13 million

Johnson & Johnson Survey Finds Awareness Gap Around Eye Changes During Menopause

Atsena Reports 18-Month ATSN-201 Results in X-Linked Retinoschisis

Stocks

Cataract

Monocular Diplopia, Foggy Vision, and Uncomfortable Binocular Vision

Sustainability in Ophthalmology

A Potential Shift in OR Management

Breaking News From the ESCRS Congress in London (Part 1 of 2)

Novel Ocular Cooling Device for Chronic Ocular Pain

MIGS Unplugged Live at ASCRS 2026: Exploring the State of Interventional Glaucoma Today

10.01.2026

SpyGlass Pharma Acquires Advanced Vision Science for Approximately $13 million

09.30.2026

Moorfields Private Launches Eye Health Assessment Service for Patients Taking GLP-1 Medications

09.29.2026

Aldeyra Plans to Appeal FDA Rejection of Reproxalap NDA

09.28.2026

Medevise Consulting to Host “Robotics in Ophthalmology” Workshop During AAO

Refractive

FDA Accepts Nanoscopes's Optogenetic Gene Therapy BLA

MIGS Unplugged Live at ASCRS 2026: Exploring the State of Interventional Glaucoma Today

Going on Offense With Epioxa

An Update on Advanced Technology IOLs

A Potential Shift in OR Management

Refractive IOLs

10.01.2026

Nidek Launches LM-1 Series Auto Lensmeter with Expanded Measurement Capabilities

09.30.2026

Moorfields Private Launches Eye Health Assessment Service for Patients Taking GLP-1 Medications

09.29.2026

Aldeyra Plans to Appeal FDA Rejection of Reproxalap NDA

09.22.2026

Sydnexis Sells Ryjunea EMEA Royalty Rights to Ligand for $23 Million

Stay Updated

Follow Eyewire News

Retina

FDA Accepts Nanoscopes's Optogenetic Gene Therapy BLA

Breaking News From the ESCRS Congress in London (Part 1 of 2)

Novel Approaches in Early and Intermediate AMD: A Mechanistic Deep Dive

Using Data to Catch Problems Early

Spotlight on UNITY® VCS: Breaking New Ground

The Fellow Eye: Episode 7

10.01.2026

Atsena Reports 18-Month ATSN-201 Results in X-Linked Retinoschisis

10.01.2026

Galimedix Highlights Patient-Tailored Microperimetry in Phase 2 eDREAM Geographic Atrophy Study

10.01.2026

Nanoscope’s Mogenry Granted Priority Review in Japan for Inherited Retinal Dystrophies

09.30.2026

Heidelberg Engineering to Showcase Imaging, Surgical Visualization Advances at AAO 2026

Glaucoma

Novel Approaches to Minimally Invasive Bleb Surgery

How to Thrive as a New Fellow

EyePoint Misses Primary Endpoint in Phase 3 Trial But Sees Promise After Analysis

Excimer Laser Treatment for Open-Angle Glaucoma

Where Plates and Fluidics Meet

Bleb Needling for Reviving a Failed Filter

10.01.2026

SpyGlass Pharma Acquires Advanced Vision Science for Approximately $13 million

09.30.2026

Heidelberg Engineering to Showcase Imaging, Surgical Visualization Advances at AAO 2026

09.30.2026

Moorfields Private Launches Eye Health Assessment Service for Patients Taking GLP-1 Medications

09.29.2026

Aldeyra Plans to Appeal FDA Rejection of Reproxalap NDA

Featured Podcasts

Ophthalmology off the Grid

New Retina Radio

Eyewire News: The Podcast

Optometry

The Pursuit of Postop Happiness

EMPOWER - Ocular Surface Disease: Latest Innovations in Dry Eye and Meibomian Gland Dysfunction

Spotlight on UNITY^® VCS: Breaking New Ground